December 11th, 2014 · 1 Comment
This post originally appeared in the Mayo Clinic Center for Regenerative blog.
Since 2007, Mayo Clinic and Cardio3 BioSciences, a biotechnology company based in Mont-Saint-Guibert, Belgium, have collaborated to advance our knowledge of disease in order to provide new solutions for patients and innovative delivery of quality care in the area of cardiac regeneration. Cardiac regenerative medicine uses reparative tools to restore damaged tissue and restitute function caused by heart disease.
Cardio3 BioSciences has successfully developed Mayo Clinic innovation leading to completion of a phase II trial on cardiopoetic stem cells in patients with heart failure. The Food and Drug Administration (FDA) has recently cleared the way for the Belgian company and Mayo Clinic to launch a phase III clinical trial of its stem cell therapy based on Mayo Clinic regenerative medicine research later this year.
Clinical application of regenerative biologics has emerged as a next generation tool that can be tailored to augment existing therapeutic strategies for otherwise incurable diseases, including heart failure. By leveraging research collaborations, such as with Cardio3 BioSciences, Mayo Clinic is positioned to transform the way we treat patients with heart disease.
In collaboration with Cardio3 BioSciences, Mayo Clinic researchers have discovered a novel way to repair a damaged heart by regenerating heart tissue.
In Mayo Clinic's breakthrough process, stem cells are harvested from a patient's bone marrow. The stem cells undergo a laboratory treatment that guides them into becoming cardiac cells. The treated cells are then injected into the patient's heart in an effort to grow healthy heart tissue.
“In regenerative medicine, the step between lab tests and clinical trials is a big one and the interaction with Cardio3 is crucial to driving Mayo Clinic's technology forward," says Atta Behfar, M.D., Ph.D., who spent several months in Belgium working with Cardio3 BioSciences. Dr. Behfar, a heart failure and transplant specialist, leads the Cardiac Program in the Mayo Clinic Center for Regenerative Medicine.
In late 2013, Mayo Clinic researchers and Cardio3 BioSciences developed a specialized catheter for transplanting stem cells into the beating heart. The novel cardiac catheter is able to dramatically improve stem cell retention in the heart. The device includes a curved needle and graded openings along the needle shaft, allowing for increased distribution of cells. The result is maximized retention of stem cells to repair the heart. The findings appear in the journal Circulation: Cardiovascular Interventions.
This new catheter is being used in the European CHART-1 clinical trials, now underway. This is the first Phase III trial to regenerate hearts of patients who have suffered heart attack damage. The studies are the outcome of years of basic science research at Mayo Clinic and earlier clinical studies with Cardio3 BioSciences and Cardiovascular Centre in Aalst, Belgium.
Watch the video below to see how stem cells are being used to treat people with heart failure.
Preferred Access Agreement
Most recently, Mayo Clinic and Cardio3 BioSciences entered into an extended collaboration agreement. It builds on a long established and productive relationship of licensing and research in the area of cardiac regeneration. The mutual hope for this work is that together Mayo and Cardio3 BioSciences can accelerate Mayo discoveries toward clinical application.
Under the Preferred Access Agreement, the parties have agreed to regular periodic meetings to review Mayo’s regenerative medicine portfolio to identify areas and projects of mutual interest. The results of these conversations could potentially lead to cooperative research projects, license agreements or introductions to third parties to further the technology.
“We are excited for the opportunity to expand our collaboration with Cardio3 and accelerate the delivery of novel therapies to patients”, says Clark Otley, M.D., Medical Director of Mayo Clinic Ventures, which works to commercialize Mayo Clinic technologies for the benefit of patients worldwide.
The Center for Regenerative Medicine continues to explore strategic relationships with academic, biotechnology/industry, government and professional associations at the local, regional, national, and international level.
October 7th, 2014 · Leave a Comment
This modified post originally appeared in the Center for Individualized Medicine blog.
Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine, took to the stage Monday morning to welcome nearly 500 attendees to the Individualizing Medicine 2014 Conference. This third annual genomics conference promises a practical approach to helping medical professionals discover and integrate genomics technology into routine patient care.
“We know we need to incorporate genomics into patient care. We have a moral obligation to bring genomics to the practice, and we have a moral obligation to do it right.”
—Gianrico Farrugia, M.D.
Clifford Hudis, M.D., immediate past president of the American Society of Clinical Oncology (ASCO), delivered the keynote address by challenging the participants to reexamine how we define value in cancer care. If the practitioners don’t, others will. He highlighted how the current way cancer drugs are developed and priced is not sustainable and that there is no relationship between cost and value. Dr. Hudis predicted that changes are coming.
“Whether we’re for or against it, pressure is building in U.S. policy circles for the federal government to take action regulating the cost of drugs and technologies. Increasing access is crucial, yet thwarting innovation is a real concern.”
—Clifford Hudis, M.D.
Several informative presentations followed. Geoffrey Ginsburg, M.D., Ph.D., Duke University, offered a look at the future of genomics and how we now have the opportunity to use genomics throughout the lifetime of a patient, in effect, from womb to tomb. Noninvasive Prenatal Tests (NIPT) is a success story in genomic medicine. Diana W. Bianchi, M.D., Tufts Medical Center, discussed how genomic testing has revolutionized prenatal screening for aneuploidy in a very short time.
— MCCIM (@MayoClinicCIM) October 5, 2014
Patrick Geraghty, CEO and Chairman of the Board of Florida Blue, outlined the innovative policies that Florida Blue is bringing to the health care community. He challenged the attendees to rethink the future of health care as a means to package the right answer in a way that meets people where they are and how they want to receive it.
The afternoon brought a number of breakout sessions, including a lively conversation on the current state of reimbursement for genomic testing, trends in ethical and social issues for genomic research, and personalized medicine for hematological cancers. Gloria Petersen, Ph.D., a researcher and a biobank manager at Mayo Clinic, talked about the goals, challenges and obligations of running a biobank.
Paul J. Hergenrother, Ph.D., University of Illinois at Urbana-Champaign, offered a detailed look at procaspace-3 activation for pet therapy, and how this relates to a forthcoming human clinical trials. Hergenrother confirmed that the dogs were veterinary patients in need of aggressive cancer treatment, not lab animals.
The 2014 Individualized Medicine Conference runs through October 8 and promises to be an informative and exciting look at the present and future of genomic medicine. If you’re unable to attend, follow along on Twitter using the hashtag #cimcon14 .
September 24th, 2014 · Leave a Comment
Watch the entire interview in the following video!
September 18th, 2014 · Leave a Comment
John Noseworthy, M.D., CEO and president of Mayo Clinic, and Tom Brokaw discussed the future of health care at this year's Google Zeitgeist conference in Paradise Valley, Ariz. Zeitgeist Minds brings together the top global thinkers and leaders across a wide spectrum including social, economic, political and cultural disciplines.
Tom Brokaw began the discussion "Facilitating Cooperative Efforts Towards Affordable Health Care for All", by stating how "nothing has an impact on society, and the welfare of society, more than health care". He then asked Dr. Noseworthy several questions related to the:
Watch the entire interview below to hear Dr. Noseworthy's responses and more!
September 11th, 2014 · Leave a Comment
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care. These new partner organizations, which represent a cross-section of health care stakeholders, are:
Optum Labs, with the largest, de-identified patient database in health care, is the first open, collaborative research and innovation center designed to accelerate health care innovation, leading to improved patient care and patient value. Read more…
September 8th, 2014 · Leave a Comment
This post originally appeared in the Mayo Clinic Center for Innovation blog. The Mayo Clinic Transform symposium is a multidisciplinary conference for thought-provoking, inspiring ideas hosted by the Mayo Clinic Center for Innovation and takes place Sept. 7–9. View the entire schedule of renowned speakers on the Transform website. If you can’t be there in person, you can watch the Transform live webcast via an external link. You're encouraged to participate digitally and virtually, in the many TweetChats. Feel free to share with your peers outside of Mayo Clinic. See webcast schedule for these digital times that have been built into the webcast — when normally the stage is “dark” during several networking times. This year, Transform has attendees from more than 14 countries and 30 states. For the first time ever, Mayo Clinic patients can watch and participate in Transform by tuning into patient channel 10. Watch this video of TXFM 2013 to hear participants try to sum up Transform in one word. Once again, journalist and commentator John Hockenberry will moderate the symposium discussions that include the following speakers:
To keep in touch with the growing transform community, join TransForum, the Center for Innovation’s online community with over 1,000 members working to transform the experience and delivery of health and health care. This online social media platform allows people to connect, create discussion groups throughout the year. The Center for Innovation is planning to bring presentations and discussion to TransForum throughout the year to keep the conversations going.
August 21st, 2014 · Leave a Comment
The future of health care needs to provide answers to the people who need them most -- the patients living with diseases and conditions that threaten their health and their lives. How is Mayo Clinic addressing this need in today's challenging health care environment? One solution lies in the efforts of Mayo Clinic Ventures and Mayo physicians and scientists who are working towards mining inventions, ideas and discoveries that will truly transform health care by improving the health and well-being of patients throughout the world.
Here's a recent post published on Mayo's In the Loop blog, which uniquely captures how Mayo Clinic Ventures makes it all happen:
"When you think about entrepreneurs and breakthrough inventions, you might imagine someone tinkering with a gadget (perhaps a doohickey or thingamajig) in a garage. You might not, however, picture a Mayo researcher tinkering with peptides to fight hypertension, creating a tracking system for viruses, or fashioning a tool to make medical information easier to read for those with poor vision. But our friends at Mayo Clinic Ventures would like us to, and a recent article series in the Minneapolis/St. Paul Business Journal gets under the hood to explore why.
Mayo's efforts to encourage entrepreneurship and support startups is not only good for medicine, but as writer Katharine Grayson suggests, bringing new ideas to the marketplace also has the potential to 'broadly impact Minnesota’s economy, with more Mayo business offspring growing up in (our own) backyard.' Jim Rogers, chair of Mayo Clinic Ventures, which commercializes Mayo Clinic technologies, tells Grayson that has meant a bit of a culture shift. And it’s required the assistance of efforts like the Mayo Clinic Business Accelerator, which provides collaborative space for new companies, venture capital firms and entrepreneurs.
To illustrate the potential of entrepreneurial endeavors, Grayson profiles three startups in a series called 'Made at Mayo.' The first article, “Mayo professor doubles as founder of text tech company,” chronicles the work of Randall Walker, M.D., Infectious Diseases, who started a company to create 'software that converts text into an easier-to-read format.' He was 'inspired by his own family history … to help people with low vision read easier,' Grayson writes. Walker Reading Technologies recently moved into the Business Accelerator space and is now working with Mayo 'to research how his text-conversion technology, called Live Ink, could make electronic medical records easier to read and manage.'
— Mayo Clinic Ventures (@MayoInvents) August 5, 2014
In another piece, called “Oncology professor launches startup to track cells and viruses,” the Biz Journal explores the work of Mayo’s Kah Whye Peng, Ph.D., to turn 'her scientific research into the foundation for a growing startup company.' Imanis Life Sciences 'sells tools and services that create a GPS-like tracking system for cells and viruses.' That allows researchers to 'use imaging technology to monitor therapies’ progress inside living animals.' And a piece called “Zumbro uses custom peptides to battle hypertension” documents the work of John Burnett, M.D., and Horng Chen, M.D. 'Their latest venture, Zumbro Discovery Inc.,' Grayson writes, 'uses peptides to treat high blood pressure in patients who haven’t benefited from traditional drugs.' Dr. Burnett says the company expects to begin clinical trials yet this year, expects to grow significantly, and its 'goal is to be the next Amgen.'
Read more about the big plans for these ventures, as well as the business behind the business, in the Business Journal series."
August 13th, 2014 · Leave a Comment
This post originally appeared in the Mayo Medical Laboratories blog.
Franklin Cockerill, M.D., chair of the Mayo Clinic Department of Laboratory Medicine and Pathology, participated in the 21st Century Cures Roundtable on Personalized Medicine hosted by the U.S. House of Representatives Energy and Commerce Committee on Wednesday, July 23.
Throughout Dr. Cockerill’s remarks, he emphasized the importance of providing proper government funding for research and regulatory bodies, harmonizing regulations, emphasizing clinical validation, ensuring patient safety, and encouraging innovation. A summary of Dr. Cockerill’s remarks have been embedded below.
According to the committee’s website, the 21st Century Cures Roundtable next brings together industry leaders to, “discuss how the rise of personalized medicine and advances in science and technology can shape the health care system in the 21st century. Specifically, the roundtable will explore how genomic sequencing and diagnostic testing, as well as the regulation of these continually evolving areas, affect innovative product development and delivery.”
Key Points from Dr. Cockerill's Remarks:
Focus on harmonizing regulations, emphasizing clinical validation, ensuring patient safety & encouraging innovation. - Cockerill #path2cures
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014
Challenges: Govt funding of scientific discovery & translating discoveries to clinical tests that benefit patients.- Cockerill #Path2Cures
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014